Institution: iPhone sales in China plummeted by 24% in the first six weeks of this year
芊芊551
发表于 2024-3-6 12:21:36
196
0
0
According to a report released by Counterpoint Research, due to fierce market competition and an unusually high sales base, the sales data of Apple's iPhone in China for the first six weeks of 2024 showed a year-on-year decrease of 24%.
On Tuesday local time, Apple's stock price fell 2.84%, dragging down US listed suppliers such as Qorvo and Broadcom.
It is worth noting that in the fourth quarter of 2023, iPhone sales in the Chinese market decreased. According to IDC data, although iPhone shipments rank first in the Chinese market, they have decreased by 2.1% year-on-year under the impact of competitors.
According to a research report by Everbright Securities, Apple's flagship product, the iPhone, is mainly driven by the average price increase of the iPhone 15 series, and its sales are not optimistic. The competition for the iPhone in the high-end mobile phone market is intensifying.
CandyLake.com 系信息发布平台,仅提供信息存储空间服务。
声明:该文观点仅代表作者本人,本文不代表CandyLake.com立场,且不构成建议,请谨慎对待。
声明:该文观点仅代表作者本人,本文不代表CandyLake.com立场,且不构成建议,请谨慎对待。
猜你喜欢
- He Xiaopeng: Overseas sales contributed over 10% in the second quarter
- It is reported that Tesla plans to start producing a six seater version of the Model Y in China by the end of 2025
- Mercedes Benz invests another 14 billion yuan to deepen its layout in China and enrich its "Made in China" product lineup with "Chinese speed"
- Ideal car firmly holds the top spot in sales among new forces, with significant long-term R&D investment and results
- Mid Autumn Festival welcomes online shopping peak, with Dingdong buying groceries and mooncake sales expected to increase by over 30% year-on-year
- Tianjing Biotechnology grants Sanofi the rights to Yulelimab in China with a down payment of 250 million yuan
- Sanofi's targeted therapy drug for chronic obstructive pulmonary disease, Dabitou, has been approved in China
- The targeted therapy drug for chronic obstructive pulmonary disease, Dabitou, has been approved in China
- Sanofi: Targeted therapy drug for chronic obstructive pulmonary disease (COPD), Dabitou, approved in China
- Toyota's global sales in August were 826863 vehicles, a year-on-year decrease of 3.1%
-
9月が終わり、映画・テレビ業界が暗躍している。最近、愛奇芸の創始者でCEOのGONG宇氏は、映画・テレビ業界が長短の変化、AIの変化、中国映画・テレビドラマの海外進出の変化の3つの変化を経験していると発表した。 ...
- 寒郁轩良
- 昨天 14:17
- 支持
- 反对
- 回复
- 收藏
-
8月のトヨタ自動車(ダイハツ自動車と日野自動車を除く、レクサスを含む)の世界生産台数は前年同月比11.2%減の709571台、世界販売台数は前年同月比3.1%減の826863台だった。 日本本土市場では、トヨタ自動車の8月 ...
- SOGO
- 3 天前
- 支持
- 反对
- 回复
- 收藏
-
ネットワーク状況監視サイトDownDetectorによると、オーディオストリーミングプラットフォームSpotifyは日曜日に約3時間にわたる障害を経験した後、正常に回復し、ピーク時には米国の4万人以上のユーザーに影響を与 ...
- hecgdge4
- 昨天 09:33
- 支持
- 反对
- 回复
- 收藏
-
百済神州(688235.SH)はA株の有名な革新薬企業で、2017-2024年上半期、同社の各期の研究開発投資はA株の化学製薬会社(申万二級)の中で最も高く、研究開発費用は合計600億元を超えた。 しかし、百済神州にとって ...
- wylz8473
- 前天 18:36
- 支持
- 反对
- 回复
- 收藏